In Response to Real-World Adverse Events After Type 2 Biologic use in Chronic Rhinosinusitis with Nasal Polyps

Laryngoscope. 2024 Oct;134(10):E32. doi: 10.1002/lary.31541. Epub 2024 Jun 4.

Authors

Marisa Dorling¹, Juan Carlos Hernaiz-Leonardo¹, Athenea Pascual¹, Arif Janjua¹, Andrew Thamboo¹, Amin R Javer¹

Affiliation

¹ Department of Otolaryngology-Head and Neck Surgery, University of British Columbia, Vancouver, British Columbia, Canada.

PMID: 38837206
DOI: 10.1002/lary.31541

No abstract available

Keywords: Mepolizumab; adverse events; antibodies, monoclonal; dupilumab; sinusitis.

Publication types

Letter